By Inti Landauro
PARIS--The U.S. Food and Drug Administration is to undertake a priority review of a treatment for atopic dermatitis, a chronic inflammatory skin disease, according to pharmaceutical firms Sanofi SA (>> Sanofi) and Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) which make the drug.
The two companies had said in June that a series of trials showed the treatment, known as dupilumab, combined with topical corticosteroids significantly improved the condition of a group of patients suffering from atopic dermatitis.
Back in 2014, the FDA had granted "breakthrough therapy" designation to dupilumab.
Large pharmaceutical companies like Sanofi are rushing to get new drugs to market to offset falling revenues from top-selling drugs whose patents recently expired.
-Write to Inti Landauro at firstname.lastname@example.org